Chemotherapy-induced gut microbiome disruption, inflammation, and cognitive decline in female patients with breast cancer.

Cognitive impairment Cytokines Differential abundance analysis Microbial diversity Objective cognition Subjective cognition

Journal

Brain, behavior, and immunity
ISSN: 1090-2139
Titre abrégé: Brain Behav Immun
Pays: Netherlands
ID NLM: 8800478

Informations de publication

Date de publication:
30 May 2024
Historique:
received: 23 01 2024
revised: 07 05 2024
accepted: 29 05 2024
medline: 2 6 2024
pubmed: 2 6 2024
entrez: 1 6 2024
Statut: aheadofprint

Résumé

Chemotherapy is notorious for causing behavioral side effects (e.g., cognitive decline). Notably, the gut microbiome has recently been reported to communicate with the brain to affect behavior, including cognition. Thus, the aim of this clinical longitudinal, observational study was to determine whether chemotherapy-induced disruption of the gut microbial community structure relates to cognitive decline and circulating inflammatory signals. Fecal samples, blood, and cognitive measures were collected from 77 patients with breast cancer before, during, and after chemotherapy. Chemotherapy altered the gut microbiome community structure and increased circulating TNF-α. Both the chemotherapy-induced changes in microbial relative abundance and decreased microbial diversity were related to elevated circulating pro-inflammatory cytokines, TNF-α and IL-6. Participants reported subjective cognitive decline during chemotherapy, which was not related to changes in the gut microbiome or inflammatory markers. In contrast, a decrease in overall objective cognition was related to a decrease in microbial diversity, independent of circulating cytokines. Stratification of subjects, via a reliable change index based on all 4 objective cognitive tests, identified objective cognitive decline in 35% of the subjects. Based on a differential microbial abundance analysis, those characterized by cognitive decline had unique taxonomic shifts (Faecalibacterium, Bacteroides, Fusicatenibacter, Erysipelotrichaceae UCG-003, and Subdoligranulum) over chemotherapy treatment compared to those without cognitive decline. Taken together, gut microbiome change was associated with cognitive decline during chemotherapy, independent of chemotherapy-induced inflammation. These results suggest that microbiome-related strategies may be useful for predicting and preventing behavioral side effects of chemotherapy.

Identifiants

pubmed: 38823430
pii: S0889-1591(24)00439-2
doi: 10.1016/j.bbi.2024.05.039
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

L D Otto-Dobos (LD)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.

C V Grant (CV)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.

A A Lahoud (AA)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.

O R Wilcox (OR)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.

L D Strehle (LD)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.

B R Loman (BR)

Center for Microbial Pathogenesis and the Oral and Gastrointestinal Microbiology Research Affinity Group, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA; Department of Animal Sciences and Division of Nutritional Sciences, University of Illinois, Urbana, IL, USA.

S Adarkwah Yiadom (S)

Division of Biostatistics, The Ohio State University, Columbus, OH, USA.

M M Seng (MM)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.

N Halloy (N)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.

K L G Russart (KLG)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.

K M Carpenter (KM)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.

E Dawson (E)

Department of Neurology, The Ohio State University, Columbus, OH, USA.

S D Sardesai (SD)

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

N O Williams (NO)

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

M E Gatti-Mays (ME)

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

D G Stover (DG)

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

P K Sudheendra (PK)

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

R Wesolowski (R)

Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

J K Kiecolt-Glaser (JK)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.

M T Bailey (MT)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA; Center for Microbial Pathogenesis and the Oral and Gastrointestinal Microbiology Research Affinity Group, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.

R R Andridge (RR)

Division of Biostatistics, The Ohio State University, Columbus, OH, USA.

L M Pyter (LM)

Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA; Department of Psychiatry and Behavioral Health, The Ohio State University, Columbus, OH, USA. Electronic address: leah.pyter@osumc.com.

Classifications MeSH